Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 210,000 shares, a decline of 88.7% from the June 15th total of 1,854,604 shares. Based on an average daily trading volume, of 22,065,408 shares, the short-interest ratio is currently 0.0 days.
Regen BioPharma Price Performance
Regen BioPharma has a 12 month low of $0.00 and a 12 month high of $0.12.
About Regen BioPharma
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
See Also
- Five stocks we like better than Regen BioPharma
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
